RheOx
Commercial- Indications
- Chronic bronchitis
Company intelligence / Profile preview
Gala Therapeutics developed pulsed electric field-based medical devices targeting pulmonary diseases and airway remodeling. Its lead product, RheOx, received CE mark in Europe and FDA breakthrough designation in the US for treating chronic bronchitis. The company merged with Galaxy Medical and Galvanize Therapeutics to form a single entity focused on pulsed electric field therapies across multiple indications. The merged company continues to advance these technologies through clinical trials and commercialization efforts.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Gala Therapeutics.